{
    "nct_id": "NCT04844528",
    "official_title": "Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)",
    "inclusion_criteria": "* Male or female subject aged ≥ 18 years.\n* Confirmed diagnosis of CLL or small lymphocytic leukemia (SLL) per iwCLL 2018 criteria.\n* History of ≥1 non-melanoma skin cancer (NMSC) diagnosed within the last 5 years\n* Adequate liver function as defined as:\n\n  * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n\n    ---Subjects with a known diagnosis of Gilbert's Syndrome: direct bilirubin ≤ 1.5x ULN\n  * AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  --Women < 50 years of age:\n  * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n  * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n  * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n* Women ≥ 50 years of age:\n\n  * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n  * Had radiation-induced menopause with last menses >1 year ago; or\n  * Had chemotherapy-induced menopause with last menses >1 year ago; or\n  * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received cytotoxic chemotherapy (including fludarabine, cyclophosphamide, bendamustine, or chlorambucil) within the last 6 months\n* Received allogeneic stem cell transplant within the last 6 months.\n* Taking nicotinamide or niacin supplements within the last 4 weeks.\n* Taken acitretin or other oral retinoids within the past 6 months\n* Received field treatment for AKs (topical use of 5-fluorouracil, imiquimod, diclofenac, retinoids; topical photodynamic therapy for AKs; laser resurfacing or chemical peel treatments for AKs) within the previous 4 weeks\n* Large areas of confluent skin cancer at baseline preventing accurate assessment and counting of individual new skin cancers\n* Need for ongoing carbamazepine use (possible interaction with nicotinamide)\n* Severe GI malabsorption that may interfere with absorption of nicotinamide (per investigator's discretion)\n* Patients with an expected life expectancy < 2 years\n* Current evidence of uncontrolled, diabetes.\n* Current evidence or history of peptic ulcer disease.\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\nNote: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n\n* Known active uncontrolled infection.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).\n* Subjects taking prohibited medications as described in Section 6.7.1. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.\n* Have ever received a solid organ transplant and are currently taking immunosuppressive medications.",
    "miscellaneous_criteria": ""
}